Medication info

Telowjeong 40/20 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Telmisartan›40mg / 1 tabletRosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Korea Union Pharm Co., Ltd.
Appearance
White oval film-coated tablet
Packaging
30 tablets/box[(10 tablets/PTP*3)]
Approval status
Expired

MFDS item code 202001849 · Approved 2020.03.17

This product's status changed to Expired on 2025.10.31. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension; improvement of dyslipidemia; inhibition of atherosclerosis and prevention of cardiovascular disease
Who takes it
Adults
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose of telmisartan is 40 mg orally once daily; a dose of 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered concomitantly with a thiazide diuretic, such as hydrochlorothiazide, an additional blood-pressure-lowering effect is observed. When increasing the dose, the maximum blood-pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When starting treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive medication may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20 milligrams once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medicine at a dose of 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. For patients taking telmisartan and rosuvastatin concomitantly, they may switch to this medicine (a fixed-dose combination containing the same amounts of each active ingredient) for convenience.

Ingredients

Manufacturer
Korea Union Pharm Co., Ltd.

Efficacy & effects

Treatment of hypertension; improvement of dyslipidemia; inhibition of atherosclerosis and prevention of cardiovascular disease

  • Essential hypertension
  • coronary artery disease
  • peripheral artery disease
  • stroke
  • transient ischemic attack
  • clinical evidence of end-organ damage
  • high-risk diabetes
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hyperlipidemia
View approved original text

This medicine is used only for patients who need to use the two drugs, telmisartan and rosuvastatin, simultaneously. Telmisartan is mainly used to reduce the risk of myocardial infarction, stroke, and mortality from cardiovascular diseases in patients aged 55 and older with essential hypertension and a high risk of cardiovascular diseases. It is also effective in cases where ACE inhibitors cannot be used. Meanwhile, rosuvastatin calcium helps treat hypercholesterolemia and dyslipidemia that are difficult to control with diet and exercise. It also contributes to delaying the progression of atherosclerosis by lowering total cholesterol and LDL cholesterol levels, and reducing the risk of stroke, myocardial infarction, and arterial revascularization in specific high-risk groups. By combining these two components, it effectively manages both hypertension and hyperlipidemia to improve cardiovascular health.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose of telmisartan is 40 mg orally once daily; a dose of 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered concomitantly with a thiazide diuretic, such as hydrochlorothiazide, an additional blood-pressure-lowering effect is observed. When increasing the dose, the maximum blood-pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When starting treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive medication may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20 milligrams once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medicine at a dose of 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. For patients taking telmisartan and rosuvastatin concomitantly, they may switch to this medicine (a fixed-dose combination containing the same amounts of each active ingredient) for convenience.

Precautions

This medication can cause serious harm to the fetus and newborn when taken during pregnancy, so it should be stopped immediately upon confirmation of pregnancy. Individuals allergic to this medication or its components should not take it. Women of childbearing potential may only take this medication if they are not likely to be pregnant and fully aware of the risks to the fetus. Patients with severely impaired liver function or problems with bile excretion should not take this medication. Patients with active liver disease or significant elevations in liver enzymes should also avoid this medication. Caution is necessary for patients with muscle disorders or a history of muscle problems when taking this medication. Patients with hereditary angioedema or a history of angioedema should not use this medication. Patients with severe renal impairment are also prohibited from taking this medication. Patients taking specific immunosuppressants and those with diabetes or moderate to severe renal impairment are prohibited from using this medication in combination with certain drugs. High doses are prohibited for patients at risk of myopathy or rhabdomyolysis, and those with risk factors should closely monitor muscle condition before and after treatment. Patients with genetic metabolic disorders such as lactose intolerance should not take this medication. Elderly patients, those with hyperkalemia, patients with compromised liver function, and others should take this medication with caution and have periodic liver enzyme and kidney function tests. Patients with specific diseases such as cardiovascular diseases, gastrointestinal diseases, and renal artery hypertension should also be careful when using this medication. This medication may interact with other antihypertensive medications, so consulting with a physician about concurrent medications is necessary. If symptoms such as muscle pain, weakness, or cramps occur, consult a doctor immediately, and if necessary, discontinue use. This medication may affect liver function, so regular liver function testing is also necessary. Additionally, this medication can cause drowsiness or dizziness while driving or operating machinery, so caution is required. In case of overdose, symptoms such as hypotension, cardiac arrhythmias, dizziness, and kidney dysfunction may occur, necessitating immediate medical attention and appropriate treatment. Keep out of reach of children and do not transfer to another container for safety.

Side effects

Headache, positional vertigo, sleep paralysis, increased blood pressure, decreased blood pressure, hypotension, elevated ALT, painful urination, rhinitis, oropharyngeal discomfort, pulmonary disease, unspecified gastrointestinal disorder, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, bad breath, fatty liver, upper respiratory infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, dyspnea, abdominal pain, diarrhea, dyspepsia, abdominal distension, vomiting, abdominal discomfort, xerostomia, liver function abnormalities, liver disorders, increased sweating, pruritus, rash, erythema, vascular edema, drug rash, toxic skin rash, eczema, urticaria, myalgia, low back pain, muscle cramps, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, increased liver enzymes, elevated serum CK, decreased hemoglobin, hypoglycemia, vascular edema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, elevated transaminases, Stevens-Johnson syndrome, eosinophilia, drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorder, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscular weakness, oculobulbar weakness, facial spasms, sensory abnormalities, paralysis, hyperventilation, pneumonia, flushing, erectile dysfunction, facial edema, alopecia, conjunctivitis, tinnitus, petechiae, palpitations, fatigue, nausea, inadequate response, cough, palpitations, myalgia, increased CK, constipation, elevated AST, weakness, joint pain, numbness, sensory abnormalities, chest discomfort, loss of appetite, abdominal distension, abnormal liver function tests, syncope, generalized pain, muscle cramping, gout, erectile dysfunction, acute renal failure, oliguria, thrombocytopenia, increased serum creatinine

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly closed container. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius. This way, the effectiveness of the medication can be preserved for a long time.

Appearance and packaging

Appearance

White oval film-coated tablet

Package unit

30 tablets/box[(10 tablets/PTP*3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.